BTKi can selectively inhibit BTK activity, and it intervenes in B-cell development by regulating the BCR signaling pathway to control the further development of various B-cell malignant diseases, and regulates the FcγR signaling pathway to treat autoimmune diseases. This evidence concerns the gene BCR and autoimmune disease.